Sharps Technology (NASDAQ:STSS – Get Free Report) and Exagen (NASDAQ:XGN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.
Profitability
This table compares Sharps Technology and Exagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sharps Technology | N/A | -157.91% | -154.40% |
| Exagen | -29.49% | -94.37% | -28.96% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Sharps Technology and Exagen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sharps Technology | 1 | 0 | 0 | 0 | 1.00 |
| Exagen | 1 | 0 | 8 | 0 | 2.78 |
Insider and Institutional Ownership
17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 1.2% of Sharps Technology shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Sharps Technology has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500.
Earnings and Valuation
This table compares Sharps Technology and Exagen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sharps Technology | $200,000.00 | 403.10 | -$282.50 million | ($831.52) | 0.00 |
| Exagen | $68.38 million | 1.47 | -$19.95 million | ($0.89) | -4.66 |
Exagen has higher revenue and earnings than Sharps Technology. Exagen is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Summary
Exagen beats Sharps Technology on 10 of the 14 factors compared between the two stocks.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Receive News & Ratings for Sharps Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sharps Technology and related companies with MarketBeat.com's FREE daily email newsletter.
